| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/18/2007 | US20070014837 System and method for use of agent in combination with subatmospheric pressure tissue treatment |
| 01/18/2007 | US20070014836 Cologne wipes |
| 01/18/2007 | US20070014835 Blood purifier |
| 01/18/2007 | US20070014834 Apparatus and methods of improved delivery of orally-administered therapeutic substances |
| 01/18/2007 | US20070014832 Therapeutic compositions and methods |
| 01/18/2007 | US20070014821 Mixing imiquimod and a base cream, then topically administering the resulting mixture, in conjunction with vaccines containing tumor necrosis factors, and valacyclovir tablets admistered by mouth, and testing for tumor markers; mammary glands |
| 01/18/2007 | US20070014820 Opioid formulations |
| 01/18/2007 | US20070014818 Liquid formulations with high concentration of human growth hormone (HGH) comprising 1,2-propylene glycol |
| 01/18/2007 | US20070014804 Peptidic nanoparticles as drug delivery and antigen display systems |
| 01/18/2007 | US20070014743 Subunguicide, and method for treating onychomycosis |
| 01/18/2007 | US20070014742 A mixture of polypeptides, as calcium binding protein for reducing bone loss and reducing renal phosphate excretion; biodrug for treating bone disorders; injectable solution or dispersed in toothpaste or a mouthwash; drug delivery gum patch |
| 01/18/2007 | US20070014738 Particles for inhalation having sustained release properties |
| 01/18/2007 | US20070014737 Administering quinine, chlorzoxazone, cyclobenzaprine, carisoprodol via vaporization |
| 01/18/2007 | US20070014735 Buccal delivery system |
| 01/18/2007 | US20070014732 Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent |
| 01/18/2007 | US20070011904 Process for co-spray drying agents with dry silicified MCC |
| 01/18/2007 | DE102005032806A1 Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten Use of a partially neutralized anionic (meth) acrylate copolymer as a coating for the manufacture of a dosage form with an active ingredient release at reduced pH values |
| 01/18/2007 | DE102005031468A1 Wässrige Suspensionen schwer wasserlöslicher oder wasserunlöslicher Wirkstoffe und daraus hergestellte Trockenpulver Aqueous suspensions of poorly water-soluble or water-insoluble drugs and derived dry powder |
| 01/18/2007 | DE102005031464A1 Emulgatorsystem, Emulsion und deren Verwendung Emulsifier, emulsion and the use thereof |
| 01/18/2007 | CA2657090A1 Clear pharmaceutical aqueous microemulsion comprising propofol and process for preparation |
| 01/18/2007 | CA2615802A1 Sustained release pharmaceutical compositions for highly water soluble drugs |
| 01/18/2007 | CA2615319A1 Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof |
| 01/18/2007 | CA2615053A1 Pharmaceutical formulations of endo-n-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1h-indazole-3-carboxamide hydrochloride |
| 01/18/2007 | CA2615031A1 Extracts of ginkgo biloba |
| 01/18/2007 | CA2614547A1 Tablet |
| 01/18/2007 | CA2614420A1 Fentanyl formulation containing an essential oil |
| 01/18/2007 | CA2614412A1 Nanoparticulate clarithromycin formulations |
| 01/18/2007 | CA2613977A1 Method for producing a powder containing xylitol crystal particles with another polyol |
| 01/18/2007 | CA2613732A1 Thermoreversible immuno-adjuvant emulsion |
| 01/18/2007 | CA2609439A1 Use of a partially neutralized, anionic (meth)acrylate copolymer as a coating for the production of a pharmaceutical form releasing active substance at reduced ph values |
| 01/18/2007 | CA2602452A1 Cyclosporin compositions |
| 01/18/2007 | CA2599531A1 Metformin methods and formulations for treating chronic constipation |
| 01/17/2007 | EP1743893A1 Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol |
| 01/17/2007 | EP1743650A2 Feline intrerferon against feline atopic dermatitis |
| 01/17/2007 | EP1743646A2 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
| 01/17/2007 | EP1743645A1 Adhesive patch |
| 01/17/2007 | EP1743644A1 Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia |
| 01/17/2007 | EP1743643A1 New formulations of substituted pyrazoline compounds |
| 01/17/2007 | EP1743638A1 Pharmaceutical formulations of substituted pyrazoline compounds |
| 01/17/2007 | EP1743631A2 Use of an amphetamine composition for regulating memory consolidation |
| 01/17/2007 | EP1743630A2 Pharmaceutical combination |
| 01/17/2007 | EP1743629A1 Process for preparing oral calcium compositions |
| 01/17/2007 | EP1743010A1 Compositions comprising tetrafluoropropene and carbon dioxide |
| 01/17/2007 | EP1742979A1 Method of producing polymeric particles with selected size, shape, morphology and composition |
| 01/17/2007 | EP1742729A1 Process for production of ionically crosslinked polysaccharide microspheres |
| 01/17/2007 | EP1742692A2 Anti-adhesion spraying |
| 01/17/2007 | EP1742669A1 Compositions and methods for enhancing contrast in imaging |
| 01/17/2007 | EP1742666A2 Preservative system |
| 01/17/2007 | EP1742665A1 Delivery system for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylacticacid derivative |
| 01/17/2007 | EP1742664A1 Permeation enhancing compositions for anticholinergic agents |
| 01/17/2007 | EP1742663A2 Compositions capable of facilitating penetration across a biological barrier |
| 01/17/2007 | EP1742661A2 Lipid compositions and use thereof |
| 01/17/2007 | EP1742645A1 Compressed pharmaceutical compositions comprising peg and electrolytes |
| 01/17/2007 | EP1742638A1 Composition comprising a diuretic and/or cardiac glycoside for the treatment of dna viral infections of the eye |
| 01/17/2007 | EP1742621A2 Agent-releasing system comprising an agent-containing patch and at least one means regulating the release of agents |
| 01/17/2007 | EP1742620A1 Method of making silicone pressure sensitive adhesives for delivering hydrophilic drugs using a silicone polyether |
| 01/17/2007 | EP1742619A2 Pulmonary malarial vaccine |
| 01/17/2007 | EP1742618A1 Novel oral formulations of ospemifene |
| 01/17/2007 | EP1742617A2 Lozenge for delivery of dextromethorphan |
| 01/17/2007 | EP1742616A2 Sustained-release microspheres and methods of making and using same |
| 01/17/2007 | EP1742615A2 Antisolvent emulsion solidification process |
| 01/17/2007 | EP1742614A1 Embolic particles |
| 01/17/2007 | EP1742613A2 Crosslinked amine polymers |
| 01/17/2007 | EP1742612A2 Particles for the delivery of active agents |
| 01/17/2007 | EP1742611A2 Remote control release of material encapsulated in polyelectrolyte multilayer microcapsules |
| 01/17/2007 | EP1742610A1 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer |
| 01/17/2007 | EP1742609A1 Dermally applicable liquid formulations for controlling parasitic arthropods on animals |
| 01/17/2007 | EP1742604A1 Skin care and cleansing compositions containing oil seed product |
| 01/17/2007 | EP1742530A2 Antimicrobial coating for inhibition of bacterial adhesion and biofilm formation |
| 01/17/2007 | EP1696873A4 Production and purification of esters of conjugated linoleic acids |
| 01/17/2007 | EP1641439B1 Tablets containing enrofloxacin and flavouring agents and/or flavours |
| 01/17/2007 | EP1545429A4 Methods and compositions for treatment of dermal conditions |
| 01/17/2007 | EP1517617B1 Compressed chewing gum |
| 01/17/2007 | EP1450762B1 Novel formulation |
| 01/17/2007 | EP1370259B1 Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder |
| 01/17/2007 | EP1322430B1 Focused acoustic energy method and device for generating droplets of immiscible fluids |
| 01/17/2007 | EP1322411B1 Colloidal suspension of submicronic particles for carrying active principles and their mode of preparation |
| 01/17/2007 | EP1301178B1 Delivery device |
| 01/17/2007 | EP1272160B1 Lipid-based drug delivery systems for topical application |
| 01/17/2007 | EP1244388B1 Intervertebral disc treatment device |
| 01/17/2007 | EP1224188B1 Nasal delivery composition comprising the methane sulphonate salt of morphine and chitosan |
| 01/17/2007 | EP1217991B1 Emulsion-based processes for making microparticles |
| 01/17/2007 | EP1094822B1 Water miscible azalide solutions |
| 01/17/2007 | EP1084170B1 Polyethylene glycol-polyorthoester, polyethylene glycol-polyorthoester-polyethylene glycol, and polyorthoester-polyethylene glycol-polyorthoester block copolymers |
| 01/17/2007 | EP0980215B2 Encapsulated material with controlled release |
| 01/17/2007 | CN2857945Y Thin-made black ointment |
| 01/17/2007 | CN1897975A Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof |
| 01/17/2007 | CN1897940A Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same |
| 01/17/2007 | CN1897929A Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid |
| 01/17/2007 | CN1897927A Transdermal pharmaceutical spray formulations comprising a vp/va copolymer and a non-aqueous vehicle |
| 01/17/2007 | CN1897926A Pharmaceutical formulations of bisphosphonates |
| 01/17/2007 | CN1897925A Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses |
| 01/17/2007 | CN1897924A Drug coating providing high drug loading and methods for providing same |
| 01/17/2007 | CN1897923A 控释药物制剂 Controlled release pharmaceutical preparation |
| 01/17/2007 | CN1897922A Process for producing pellets for pharmaceutical compositions |
| 01/17/2007 | CN1897921A Consumer customized dosage forms |
| 01/17/2007 | CN1897920A System and method for transdermal vaccine delivery |
| 01/17/2007 | CN1897919A Stabilized formulations of phosphatidylserine |
| 01/17/2007 | CN1897918A Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
| 01/17/2007 | CN1897917A Suspension of loteprednol etabonate and tobramycin for topical ophthalmic use |